News >

Risks for Breast, Ovarian Cancers Could Be Found With Multigene Panel Testing

Greg Kennelty
Published: Thursday, Jul 14, 2016

Allison W. Kurian, MD, MSc

Allison W. Kurian, MD, MSc

In nearly 100,000 patients who were clinically tested for hereditary cancer risk, utilization of multigene panel sequencing was found to detect ovarian cancer-associated mutations in 11 genes, according to results of a study presented at the 2016 ASCO Annual Meeting.1

Using a panel of 25 genes, 14% of the 95,561 women from the database were found to have a genetic mutation. One-third of patients harbored unexpected genes—such as breast cancer genes—which are described as uncommon to appear on standard tests.

A second study, also presented at the meeting2, examined the potential harms of multiplex testing for cancer risk, such as unwarranted surgery or adverse psychological effects. However, results showed that, at a 3-month follow-up after genetic testing, the rates of patient distress, intrusive thoughts, or regret of testing were found to be low.

In an interview with OncLive, lead study author on both trials Allison W. Kurian, MD, MSc, associate professor of Medicine and of Health Research and Policy, Stanford University School of Medicine, discusses these studies utilizing multigene panels to uncover previously undetected risks in patients with breast and ovarian cancer, as well as provides insight on the significance of BRCA testing.

OncLive: Can you give us an overview of your ongoing study on multigene panel testing?

Kurian: This is an interim report of a clinical trial that we've been doing, and that trial is evaluating a multiple-gene panel test. Instead of the older practice of testing for only one or two genes when people come in with a family history of breast cancer or colon cancer, this is a panel that tests 25 genes. This is quite a few more than we usually test.

The goals of this study are to understand the yield when we do this bigger panel and to determine what the proportion of patients are that have harmful mutations, as well as variants of uncertain significance. We also want to very much understand the patient's perspective and the outcomes. Is this information that upsets patients? Does it drive them to do things that we would rather them not do, such as preventive surgery that might be unwarranted based on the results? Do they have high levels of distress? That's been the intention of the study.

This is an interim analysis where we've enrolled 1000 of the total 2000 patients. The study enrolled rather quickly–it was 1000 within the first year at 3 centers. One of the real strengths of the study that we see is the diversity of the patients, both in terms of ethnicity and sociodemographic background. One-third of the patients had no higher than high school as their level of education; I believe 30% to 40% were of Hispanic ethnicity and about 29% were Spanish-speaking only. It's a nice, diverse population, and one where we think we would have a good chance of really seeing the impact on a real-world population of genetic testing. This is not what we see often in a tertiary referral center, so we like that a lot.

What we found was that about 3 months after genetic testing, which are the results we recently presented, the rates of distress, of intrusive thoughts, or regret of testing were really very low. We were encouraged that there doesn't seem to be an early signal for harm from this kind of testing from a psychological perspective. We also saw a very low use of preventive surgery among patients who had negative or uncertain results, which was encouraging to see, and we saw a good understanding of the results in terms of patients notifying their family members when a result was positive.

Those were the main findings. The caveats are that the follow-up is short at this point; it's only about 3 months follow-up. We're going to follow patients much longer, so really this is an early safety signal at this point and needs further follow-up.

Can you also talk about gene panel testing for possible ovarian cancer risks?

This is a study focused on understanding the level of cancer risk with gene mutations, again using one of these large multiple-gene panels. I think the significance here is that more and more patients are being tested with these panels, and much of the time the genes on the panels are associated with risks that are not really well-defined. For example, we might have a patient who had breast cancer and maybe we find a mutation in a gene like CHEK2 or ATM. We think we're beginning to understand the breast cancer risk, but we really don't know the associated ovarian cancer risks, and that's really important because if the risk is high, this woman should be protected by being offered preventive surgery. So it would really change care.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Publication Bottom Border
Border Publication